膀癌中的与氧化还原相关的lncRNA特征
Fuguang Zhao1,2, Hui Xie3, Yawei Guan1,2
1Department of Urology, The Third Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, 100039, P.R. China.
Scientific reports
|November 16, 2024
概括
这项研究确定了八种与氧化还原相关的长非编码RNA (lncRNAs),它们形成了预测膀癌 (BCa) 预后的特征. 这个签名准确地预测了患者的生存率和潜在的治疗反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 转毒状态对癌症的发展和进展至关重要.
- 长非编码RNAs (lncRNAs) 可以调节与癌症相关的氧化还原调节.
- 对于膀癌 (BCa) 的预后,需要一种特定的与氧化还原相关的lncRNA签名.
研究的目的:
- 建立一种新的与氧化还原相关的lncRNA签名,以改善BCa患者的预后预测.
- 确定与BCa中的氧化还原状态和生存相关的关键lncRNAs.
- 评估签名的预测准确性和临床相关性.
主要方法:
- 从癌症基因组图谱 (TCGA) 下载了转录组和临床数据.
- 采用单变Cox,LASSO和多变Cox回归分析来确定预后 lncRNAs.
- 使用8个选择的与氧化还原相关的lncRNA构建了一个风险模型,并进行了生存分析和基因组丰富分析 (GSEA).
主要成果:
- 已经确定了八个与氧化还原相关的lncRNAs (AC018653.3,AC090229.1,AL357033.4,AL662844.4,AP003352.1,LINC00649,LINC01138,MAFG-DT) 的签名.
- 高风险组的整体存活率明显低于低风险组 (p < 0.001).
- 该签名显示出比传统的临床病理特征更高的预测准确性,并在高风险组中确定了丰富的MAPK和Wnt信号通路.
结论:
- 开发的八个与氧化还原相关的lncRNA签名准确且独立地预测BCa患者的预后.
- 签名可以指导个性化治疗策略,因为高风险患者对特定化疗的敏感性增加.
- 作为MAFG-DT的标,IGF2BP2的过度表达与BCa中较差的OS相关.
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Non-LTR Retrotransposons
11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K


